PD-L1 Monoclonal Antibody

CSB-MA878942A1m

Rate （5.0）
Review （2）
Citation （1）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Raised in: Mouse

Application: ELISA, WB, IHC, IF, FC

Send an Inquiry

Start an on-line Chat

Orders can only be placed from within the U.S.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q9NZQ7

Alternative Names

B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD274 antibody; CD274 antigen antibody; CD274 molecule antibody; MGC142294 antibody; MGC142296 antibody; OTTHUMP00000021029 antibody; PD L1 antibody; PD-L1 antibody; PD1L1_HUMAN antibody; PDCD1 ligand 1 antibody; PDCD1L1 antibody; PDCD1LG1 antibody; PDL 1 antibody; PDL1 antibody; Programmed cell death 1 ligand 1 antibody; Programmed death ligand 1 antibody; RGD1566211 antibody

Raised in

Mouse

Species Reactivity

Human

Immunogen

Recombinant Human Programmed cell death 1 ligand 1 protein (19-238AA)

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

IgG2b

Clone No.

14D8C2

Purification Method

>95%, Protein G purified

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Tested Applications

ELISA, WB, IHC, IF, FC

Recommended Dilution

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:50-1:200
IF	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Protocols

ELISA Protocol Western Blotting(WB) Protocol Immunohistochemistry (IHC) Protocol Immunofluorescence (IF) Protocol Flow Cytometry (FC) Protocol

Datasheet & COA

Antibody FAQs

Images

Western Blot
Positive WB detected in: A549 whole cell lysate, PC-3 whole cell lysate, HepG2 whole cell lysate, MCF-7 whole cell lysate, 293 whole cell lysate, Hela whole cell lysate
All lanes: PD-L1 antibody at 1:1000
Secondary
Goat polyclonal to Mouse IgG at 1/10000 dilution
Predicted band size: 34, 21 kDa
Observed band size: 55, 70 kDa
IHC image of CSB-MA878942A1m diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
IHC image of CSB-MA878942A1m diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
Immunofluorescence staining of 293 cells with CSB-MA878942A1m at 1:150, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).
Immunofluorescence staining of A549 cells with CSB-MA878942A1m at 1:150, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).
Immunofluorescence staining of Hela cells with CSB-MA878942A1m at 1:150, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).
Overlay histogram showing 293 cells stained with CSB-MA878942A1m (red line) at 1:300. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
Overlay histogram showing A549 cells stained with CSB-MA878942A1m (red line) at 1:300. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
Overlay histogram showing Hela cells stained with CSB-MA878942A1m (red line) at 1:300. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

Description

In the preparation of this PD-L1 monoclonal antibody, a mouse is selected as the host animal. The recombinant human PD-L1 protein (19-238aa) was injected into the mouse to induce an immune response. Next, the spleen cells were removed from the immunized mouse and then fused with myeloma cells to generate hybridomas. PD-L1 antibody-producing-hybridomas were selected to culture. The PD-L1 monoclonal antibody was extracted from the mouse ascites and underwent purification by protein G affinity chromatography. Its specificity for human PD-L1 protein was validated in multiple applications, including ELISA, WB, IHC, IF, and FC.

PD-L1 plays a key role in regulating the immune system. When PD-L1 binds to its receptor PD-1 on T cells, it inhibits the T cell response and prevents it from attacking PD-L1-expressing cells. This mechanism is often exploited by cancer cells, which can upregulate PD-L1 expression to evade destruction by the immune system. Targeting PD-L1 with immunotherapy drugs has become an important treatment strategy for some types of cancer.

Customer Reviews and Q&A

■ Customer Reviews

Average Rating:

5.0 - 2 reviews

Submit a Review here

Applications : a:1:{i:0;a:2:{i:0;s:17:"Western Blot (WB)";i:1;s:0:"";}}

Sample type: Human granulosa cell carcinoma KGN

Sample dilution: 1:1500

Review: describe

By Anonymous

Applications : a:1:{i:0;a:2:{i:0;s:17:"Western Blot (WB)";i:1;s:0:"";}}

Review: describe

By Anonymous

Citations

PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway F Wang,/,2022

Target Background

Function

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.

Gene References into Functions

an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1 causing T cell exhaustion PMID:29593314
hypothesized that an oncolytic poxvirus would attract T cells into the tumour, and induce PD-L1 expression in cancer and immune cells, leading to more susceptible targets for anti-PD-L1 immunotherapy PMID:28345650
multivariate Cox hazards regression analysis identified ALCAM and PD-L1 (both P < 0.01) as potential independent risk factors for primary diffuse pleural mesotheliomas PMID:28811252
miR-191-5p was identified to have negative correlation with PD-L1 expression and acted as an independent prognostic factor of OS in patients with colon adenocarcinoma. PMID:30045644
our findings suggest a regulatory mechanism of PD-L1 through data analysis, in vitro and vivo experiments, which is an important factor of immune evasion in GC cells, and CXCL9/10/11-CXCR3 could regulate PD-L1 expression through STAT and PI3K-Akt signaling pathways in GC cells. PMID:29690901
CD163(+)CD204(+) Tumor-associated macrophages possibly play a key role in the invasion and metastasis of oral squamous cell carcinoma by T-cell regulation via IL-10 and PD-L1 production. PMID:28496107
Results demonstrated that the expression of PDL1 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. Blocking PDL1 can inhibit tumor growth by activating CD4+ and CD8+ T cells involved in the immune response. PMID:30272332
miR-574-3p was identified to potentially regulate PD-L1 expression in chordoma, which inversely correlated with PD-L1. Positive PD-L1 expression on tumor cells was associated with advanced stages and TILs infiltration, whereas decreased miR-574-3p level correlated with higher muscle invasion, more severe tumor necrosis and poor patient survival. PMID:29051990
PD-L1 expression was detected in 69% of cases of primary melanoma of the vulva PMID:28914674
PD-L1 tumor cell expression is strongly associated with increased HIF-2alpha expression and presence of dense lymphocytic infiltration in clear cell renal cell carcinoma. PMID:30144808
Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma PMID:30454551
PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer PMID:28782638
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma PMID:30050132
Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas PMID:29122656
Positive PD-L1 expression is indicative of worse clinical outcome in Xp11.2 renal cell carcinoma. PMID:28522811
PD-L1 expression in cancer cells is upregulated in response to DNA double-strand break. PMID:29170499
Targeting PD-L1 Protein is an efficient anti-cancer immunotherapy strategy. (Review) PMID:30264678
Suggest that PD-L1 may play a relevant role in metastatic spread and may be a candidate prognostic biomarker in cutaneous squamous cell carcinoma. PMID:29742559
PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PMID:29874226
SLC18A1 might complement other biomarkers currently under study in relation to programmed cell death protein 1/programmed cell death protein ligand 1 inhibition PMID:30194079
Low PDL1 expression is associated with mammary and extra-mammary Paget disease. PMID:29943071
Low PDL1 mRNA expression is associated with non-muscle-invasive bladder cancer. PMID:29150702
we found that in advanced stage NSCLC patients who received nivolumab, the C allele of PD-L1 rs4143815 and the G allele of rs2282055 were significantly associated with better ORR and PFS. This is the first report that PD-L1 SNP, which was thought to increase PD-L1 expression, is associated with a response to nivolumab. PMID:28332580
PD-L1 expression differs between the two components of lung ASCs. Given the complexity of lung ASCs, their treatment outcomes may be improved by administration of both EGFR TKIs and anti-PD-1/PD-L1 antibodies in cases where EGFR mutations are present and PD-L1 is overexpressed. PMID:28387300
IDO and B7-H1 expressions were observed in patients with pancreatic carcinoma tissues and are important markers for PC malignant progression PMID:30029936
There was higher programmed cell death protein ligand-1(PD-L1) expression in post-treatment EBV DNA-positive patients. Post-treatment positive EBV DNA status maybe a useful biomarker of worse outcomes in early stage -stage extranodal natural killer/T cell lymphoma. PMID:30116872
PD-L1 is a critical TTP-regulated factor that contributes to inhibiting antitumor immunity. PMID:29936792
Structural and functional analyses unexpectedly reveal an N-terminal loop outside the IgV domain of PD-1. This loop is not involved in recognition of PD-L1 but dominates binding to nivolumab, whereas N-glycosylation is not involved in binding at all. PMID:28165004
While mutational analysis appeared similar to that of older patients with OCSCC who lack a smoking history, a comparatively high degree of PD-L1 expression and PD-1/L1 concordance (P=0.001) was found among young female OCSCC patients. PMID:28969885
PD-L1 expression is predictive of survival in diffuse large B-cell lymphoma, irrespective of rituximab treatment. PMID:29748856
PD-L1 expression was augmented on CD8+ T cells in BALF of a patient with smoldering adult T-cell lymphoma and Pneumocystis jiroveci pneumonia. This suggested that the PD-1-PD-L1 system may suppress not only antitumor immunity but also host defense against pathogens and thereby allow establishment of chronic HTLV-1 infection and immunodeficiency. PMID:28967040
MUC1 drives PD-L1 expression in triple-negative breast cancer cells. PMID:29263152
Positive PD-L1 expression was found in 36.8% of inflammatory breast carcinoma (IBC) samples but was not significantly associated with the clinicopathologic variables examined. Worse overall survival (OS) was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative. PMID:29425258
PD-L1 expression display a highly variable distribution in clear cell renal cell carcinomas and this particularity should be kept in mind when selecting the tumor samples to be tested for immunotherapy. PMID:29661736
Report relatively low level PD-L1 positivity in treatment-naive acinar prostatic adenocarcinoma. PMID:30257853
High PD-L1 expression is associated with pulmonary metastases in head and neck squamous cell carcinoma. PMID:29937180
these data suggest that DNA-damage signaling is insufficient for upregulating PD-L1 in normal human dermal fibroblasts PMID:29859207
High CD274 expression is associated with Oral Squamous Cell Carcinoma. PMID:28669079
This study provides important evidence of higher levels of agreement of PD-L1 expression in pulmonary metastasis compared with in multiple primary lung cancer, and high positivity of PD-L1 expression in pulmonary metastatic lesions with wild-type EGFR in an Asian population. PMID:29254651
High PD-L1 expression is associated with Mycobacterium avium complex-induced lung disease. PMID:28169347
PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in metastatic breast cancer PMID:29063313
The expression of PDL1 was significantly increased following treatment with gefitinib. PMID:29901173
These results demonstrated that the IFNGinduced immunosuppressive properties of B7H1 in human BM and WJMSCs were mediated by STAT1 signaling, and not by PI3K/RACalpha serine/threonineprotein kinase signaling PMID:29901104
PD-1/PD-L1 expression is a frequent occurrence in poorly differentiated neuroendocrine carcinomas of the digestive system. PMID:29037958
High CD274 expression is associated with Epithelial Ovarian Cancer. PMID:30275195
Studied expression levels of CD274 molecule (PD-L1) in thymic epithelial tumors. Found PD-L1 expression level correlated with the degree of TET malignancy. PMID:29850538
Authors assessed PD-L1 expression in both tumor cells and tumor-infiltrating immune cells in the tumor specimens (complete histological sections, not tissue microarray). PMID:28420659
We conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors, expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling PMID:29843813
PD-L1 expression is a prognostic factor related with poor survival among patients that developed non-small cell lung cancer. PMID:29614306
The inhibition of PTEN also reduced the cancer effects of CD4+ T cells on non-small cell lung cancer (NSCLC) cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4+ T cells in human NSCLC through PD-L1 expression via the PTEN pathway. PMID:29767245

Hide All

Subcellular Location

Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Endomembrane system; Single-pass type I membrane protein.

Protein Families

Immunoglobulin superfamily, BTN/MOG family

Tissue Specificity

Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.

Database Links

HGNC: 17635

UNIGENE: Hs.521989

KEGG: hsa:29126

STRING: 9606.ENSP00000370989

OMIM: 605402

Promotions